Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial

NCT04383743 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04383743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04383743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Completed
Start date
November 24, 2020
Completion date
March 4, 2025
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle invasive bladder carcinoma, stage ii bladder cancer ajcc v8, stage iiia bladder cancer ajcc v8